Your browser is no longer supported. Please, upgrade your browser.
Settings
SLS SELLAS Life Sciences Group, Inc. daily Stock Chart
SLS [NASD]
SELLAS Life Sciences Group, Inc.
Index- P/E- EPS (ttm)-11.21 Insider Own2.20% Shs Outstand6.38M Perf Week-13.49%
Market Cap22.98M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float6.58M Perf Month34.92%
Income-27.20M PEG- EPS next Q-0.64 Inst Own14.70% Short Float3.99% Perf Quarter58.88%
Sales- P/S- EPS this Y93.10% Inst Trans146.14% Short Ratio1.28 Perf Half Y-26.09%
Book/sh1.26 P/B2.70 EPS next Y55.80% ROA-135.70% Target Price- Perf Year-87.91%
Cash/sh0.99 P/C3.43 EPS next 5Y- ROE-278.00% 52W Range1.46 - 38.50 Perf YTD-20.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.04% Beta1.78
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low137.11% ATR0.29
Employees5 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)65.96 Volatility10.00% 9.77%
OptionableNo Debt/Eq0.00 EPS Q/Q94.00% Profit Margin- Rel Volume2.66 Prev Close3.40
ShortableYes LT Debt/Eq0.00 EarningsMay 14 AMC Payout- Avg Volume204.39K Price3.45
Recom2.00 SMA2010.52% SMA5046.40% SMA200-16.01% Volume290,867 Change1.47%
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Jun-03-20 09:00AM  
May-22-20 08:30AM  
May-18-20 08:30AM  
May-14-20 04:33PM  
May-07-20 08:00AM  
Apr-28-20 08:30AM  
Apr-16-20 08:30AM  
Mar-18-20 08:30AM  
Mar-13-20 08:30AM  
Mar-10-20 12:03PM  
Feb-26-20 08:30AM  
Feb-14-20 08:30AM  
Feb-11-20 08:30AM  
Feb-10-20 08:45AM  
Jan-13-20 08:30AM  
Jan-10-20 07:13AM  
Jan-09-20 09:00AM  
Jan-08-20 08:30AM  
Jan-06-20 08:15AM  
Dec-04-19 08:00AM  
Nov-19-19 01:28PM  
Nov-14-19 04:30PM  
Nov-08-19 08:00AM  
Nov-06-19 09:20AM  
Aug-14-19 04:15PM  
Aug-05-19 08:30AM  
Jul-31-19 08:15AM  
Jun-22-19 10:10AM  
Jun-18-19 04:33PM  
Jun-14-19 08:30AM  
Jun-03-19 08:30AM  
May-17-19 08:03AM  
May-15-19 04:30PM  
Apr-04-19 08:30AM  
Mar-22-19 08:39AM  
Mar-04-19 08:30AM  
Feb-26-19 10:49AM  
08:30AM  
Feb-12-19 08:45AM  
Jan-31-19 08:30AM  
Jan-08-19 08:30AM  
Dec-06-18 08:30AM  
Nov-30-18 08:30AM  
Nov-28-18 08:30AM  
Nov-26-18 08:30AM  
Nov-15-18 07:30AM  
Nov-12-18 07:00AM  
Nov-09-18 10:00AM  
08:55AM  
08:30AM  
Nov-08-18 08:45AM  
Nov-06-18 09:30AM  
Nov-02-18 08:00AM  
Nov-01-18 10:05AM  
Oct-22-18 07:00AM  
Oct-19-18 08:05AM  
Oct-16-18 01:12PM  
Oct-15-18 08:30AM  
Oct-02-18 04:01PM  
Sep-24-18 04:30PM  
Sep-13-18 08:30AM  
Aug-16-18 09:37AM  
Aug-15-18 08:00AM  
Jul-20-18 11:05AM  
08:30AM  
Jul-16-18 11:23AM  
Jul-12-18 08:45AM  
07:20AM  
Jun-26-18 07:46AM  
Jun-07-18 07:35AM  
Jun-04-18 08:45AM  
Jun-01-18 08:45AM  
May-17-18 08:45AM  
May-09-18 04:30PM  
May-02-18 08:45AM  
Apr-20-18 08:45AM  
Apr-16-18 09:00AM  
Apr-05-18 02:43PM  
Apr-02-18 12:18PM  
08:40AM  
Mar-29-18 01:59PM  
Mar-21-18 08:45AM  
Mar-19-18 08:45AM  
Mar-15-18 08:45AM  
Mar-13-18 04:15PM  
Mar-07-18 09:00AM  
Mar-05-18 04:15PM  
Feb-27-18 08:45AM  
Feb-06-18 08:30AM  
Feb-01-18 04:01PM  
Jan-24-18 08:55AM  
Jan-23-18 02:03PM  
Jan-06-18 03:10PM  
Dec-29-17 04:46PM  
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.